検査と技術51巻11号

2023年11月発行

トピックス

加齢関連疾患に対する選択的老化細胞除去というアプローチ

著者： 清水逸平¹

所属機関： ¹国立循環器病研究センター心不全・移植部門／心血管老化制御部

ページ範囲：P.1272 - P.1274

はじめに

　加齢や加齢性疾患に伴い，全身の臓器で老化細胞が蓄積する．これらの細胞が臓器の機能的・構造的リモデリングを進展させることを示すエビデンスが集積されている．老化細胞は老化関連分泌表現型（senescence-associated secretory phenotype：SASP）を介して慢性炎症を惹起し，動脈硬化性疾患，心不全，非アルコール性脂肪性肝炎，慢性腎臓病などの加齢性疾患の病態を増悪させる．しかし，細胞老化は無秩序な細胞分裂を抑制する役割も担うため，細胞老化を抑制することでがん化の懸念が生じる．

　そこで今日，“選択的老化細胞除去”というアプローチが注目されている．本稿では，老化細胞を標的とした治療，特に選択的老化細胞除去薬について解説する．

参考文献

1）Nelson G, et al. A senescent cell bystander effect: senescence-induced senescence. Aging Cell 2012; 11: 345-349.

2）Baker DJ, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 2016; 530: 184-189.

3）Chang J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016; 22: 78-83.

4）Walaszczyk A, et al. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging Cell 2019; 18: e12945.

5）Triana-Martínez F, et al. Identification and characterization of Cardiac Glycosides as senolytic compounds. Nat Commun. 2019; 10: 4731.

6）Johmura Y, et al. Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. Science 2021; 371: 265-270.

7）Zhu Y, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015; 14: 644-658.

8）Roos CM, et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 2016; 15: 973-977.

9）Lewis-McDougall FC, et al. Aged-senescent cells contribute to impaired heart regeneration. Aging Cell 2019; 18: e12931.

10）Xu M, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018; 24: 1246-1256.

11）Xu M, et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife 2015; 4: e12997.

highly expressing cells in adipose tissue alleviates insulin resistance in obesity. Cell Metab. 2022; 34: 75-89.e8.

13）Hickson LJ, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 2019; 47: 446-456.

14）Suda M, et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat Aging. 2021; 1: 1117-1126.

15）Chaib S, et al. Cellular senescence and senolytics: the path to the clinic. Nat Med. 2022; 28: 1556-1568.

16）Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine 2019; 40: 554-563.

17）Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 2018; 36: 18-28.

18）Jeon OH, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017; 23: 775-781.

19）Dagher O, et al. Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery. Front Cardiovasc Med. 2021; 8: 741542.

20）Sweeney M, et al. Therapeutic opportunities for senolysis in cardiovascular disease. FEBS J. 2023; 290: 1235-1255.